Trial Profile
Itacitinib Monotherapy for Low Risk Graft-vs-Host Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Feb 2023
Price :
$35
*
At a glance
- Drugs Itacitinib (Primary)
- Indications Graft-versus-host disease
- Focus Registrational; Therapeutic Use
- 12 Sep 2022 Results published in the Blood
- 24 Jun 2022 Status changed from active, no longer recruiting to completed.
- 31 Aug 2021 Status changed from recruiting to active, no longer recruiting.